EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety and tolerability of a therapy
with EndoTAG-1 + paclitaxel in combination and EndoTAG-1 alone as a rescue therapy for
patients with relapsed or metastatic triple receptor negative breast cancer (a special
subgroup of breast cancer).